Literature DB >> 26291017

Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.

Pavel A Levin1, Melissa Mayer2, Sharon Hoskin2, Joseph Sailors3, Dwight H Oliver3, David E Gerber4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26291017      PMCID： PMC5158309          DOI： 10.1097/JTO.0000000000000571

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.

Authors:  Kevin S Scher; Juan-Sebastian Saldivar; Michael Fishbein; Alberto Marchevsky; Karen L Reckamp
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

2.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

Review 3.  Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?

Authors:  Kristell Bastide; Nicolas Ugolin; Céline Levalois; Jean-François Bernaudin; Sylvie Chevillard
Journal:  Lung Cancer       Date:  2009-12-08       Impact factor: 5.705

Review 4.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Rev Cancer       Date:  2008-09-11       Impact factor: 60.716
  4 in total
  24 in total

1.  Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer.

Authors:  Shinji Shinohara; Yoshinobu Ichiki; Yukiko Fukuichi; Yohei Honda; Masatoshi Kanayama; Akihiro Taira; Yusuke Nabe; Taiji Kuwata; Masaru Takenaka; Soichi Oka; Yasuhiro Chikaishi; Ayako Hirai; Naoko Imanishi; Koji Kuroda; Kazue Yoneda; Hirotsugu Noguchi; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

Authors:  Tri Le; Joseph Sailors; Dwight H Oliver; Melissa Mayer; Sharon Hoskin; David E Gerber
Journal:  Lung Cancer       Date:  2017-01-11       Impact factor: 5.705

3.  Histologic Changes in Non-Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples.

Authors:  Chang Gok Woo; Seung-Myoung Son; Ho-Chang Lee; Hye Sook Han; Ki Hyeong Lee; Dohun Kim; Eung-Gook Kim; Ok-Jun Lee
Journal:  Cancer Res Treat       Date:  2021-09-24       Impact factor: 5.036

Review 4.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

5.  Histologic transformation of non-small-cell lung cancer in brain metastases.

Authors:  Meng Jiang; Xiaolong Zhu; Xiao Han; Haiyan Jing; Tao Han; Qiang Li; Xiao Ding
Journal:  Int J Clin Oncol       Date:  2018-11-16       Impact factor: 3.402

Review 6.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

7.  The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Authors:  Shang-Gin Wu; Yi-Nan Liu; Meng-Feng Tsai; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; James Chih-Hsin Yang; Yueh-Feng Wen; Jin-Yuan Shih
Journal:  Oncotarget       Date:  2016-03-15

8.  Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.

Authors:  Jikai Zhao; Jinchen Shao; Ruiying Zhao; Rong Li; Keke Yu; Lei Zhu; Jie Zhang
Journal:  Thorac Cancer       Date:  2017-11-09       Impact factor: 3.500

9.  Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.

Authors:  Hyung Kyu Park; Youjeong Seo; Yoon-La Choi; Myung-Ju Ahn; Joungho Han
Journal:  J Pathol Transl Med       Date:  2017-04-04

Review 10.  Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Authors:  Emma-Anne Karlsen; Sam Kahler; Joan Tefay; Shannon R Joseph; Fiona Simpson
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.